Tilray Brands (NASDAQ:TLRY) Trading 3.8% Higher – Here’s Why

Posted by Stanley Muller on May 20th, 2026

Tilray Brands, Inc. (NASDAQ:TLRY – Get Free Report)’s stock price traded up 3.8% on Wednesday . The company traded as high as $5.48 and last traded at $5.41. 2,621,521 shares were traded during trading, a decline of 41% from the average session volume of 4,474,375 shares. The stock had previously closed at $5.21.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Zacks Research raised Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 11th. Roth Mkm raised Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a research note on Thursday, April 2nd. Canaccord Genuity Group assumed coverage on Tilray Brands in a research note on Tuesday, January 27th. They issued a “hold” rating for the company. Wall Street Zen raised Tilray Brands from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, TD Cowen dropped their price target on Tilray Brands from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $11.50.

Read Our Latest Report on Tilray Brands

Tilray Brands Price Performance

The business has a 50 day moving average of $6.46 and a 200 day moving average of $8.29. The company has a market cap of $630.53 million, a PE ratio of -0.40 and a beta of 1.94. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.79 and a quick ratio of 1.66.

Tilray Brands (NASDAQ:TLRY – Get Free Report) last posted its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.10). The firm had revenue of $206.73 million during the quarter, compared to the consensus estimate of $201.35 million. Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.During the same quarter last year, the company posted ($0.87) EPS. As a group, research analysts predict that Tilray Brands, Inc. will post -0.58 EPS for the current year.

Insider Transactions at Tilray Brands

In other Tilray Brands news, Director David G. Hopkinson sold 33,556 shares of the stock in a transaction on Tuesday, April 21st. The stock was sold at an average price of $6.94, for a total value of $232,878.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.84% of the company’s stock.

Hedge Funds Weigh In On Tilray Brands

Institutional investors have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC bought a new position in Tilray Brands in the fourth quarter worth $38,000. Engineers Gate Manager LP bought a new position in Tilray Brands in the fourth quarter worth $126,000. Oppenheimer & Co. Inc. bought a new position in Tilray Brands in the third quarter worth $25,000. R Squared Ltd bought a new position in Tilray Brands in the first quarter worth $94,000. Finally, Apollon Wealth Management LLC bought a new position in shares of Tilray Brands during the first quarter valued at $96,000. Institutional investors own 9.35% of the company’s stock.

About Tilray Brands

(Get Free Report)

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.